Prognostic relevance of CD56 expression in multiple myeloma: A study including 107 cases treated with high-dose melphalan-based chemotherapy and autologous stem cell transplant

Leukemia and Lymphoma

Volumn 47, Issue 1, 2006, Pages 43-47

  Chang, Hong ^a,b   Samiee, Sara ^a   Yi, Qi Long ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

Author keywords

CD56; Multiple myeloma; Prognostic factors; Stem cell transplantation

Indexed keywords

CD56 ANTIGEN; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN; MELPHALAN; PARAFFIN; PROTEIN P53; VINCRISTINE;

ADOLESCENT; ADULT; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE LESION; BONE MARROW; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CHROMOSOME 13Q; CHROMOSOME DELETION; CONTROLLED STUDY; DISEASE COURSE; DRUG DOSE REGIMEN; DRUG MEGADOSE; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENETIC RISK; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN LOCALIZATION;

ADULT; AGED; ANTIGENS, CD56; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MELPHALAN; MIDDLE AGED; MULTIPLE MYELOMA; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RETROSPECTIVE STUDIES; SURVIVAL RATE; TIME FACTORS; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME;

EID: 30844473519     PISSN: 10428194     EISSN: None     Source Type: Journal    
DOI: 10.1007/11807964_5     Document Type: Article

References (15)

1. Van Camp, B and Durie, B and Spier, C and De Waele, M and Van Riet, I and Vela, E and (1990) Plasma cell in multiple myeloma express a natural killer cell-associated antigen: CD56 (NKH-1; Leu-19) Blood, 76, pp. 377 - 382.
2. Kaiser, U and Auerbach, B and Oldenburg, M. (1996) The neural cell adhesion molecule NCAM in multiple myeloma Leukemia & Lymphoma, 20, pp. 389 - 395.
3. Mateo, G and Castellanos, M and Rasillo, A and Gutierrez, N and Montalban, M and Martin, M and (2005) Genetic abnormalities and patterns of antigenic expression in multiple myeloma Clinical Cancer Research, 15, pp. 3661 - 3667.
4. Sahara, N and Takeshita, A and Shigeno, K and Fujisawa, S and Takeshita, K and Naito, K and (2002) Clinicopathological and prognostic characteristics of CD56-negative multiple myeloma British Journal of Haematology, 117, pp. 882 - 885.
5. Mathew, P and Ahmann, G and Witzig, T and Roche, P and Kyle, R and Greipp, P. (1995) Clinicopathological correlates of CD56 expression in multiple myeloma: A unique entity? British Journal of Haematology, 90, pp. 459 - 461.
6. Attal, M and Harousseau, J and Stoppa, A and Sotto, J and Fuzibet, J and Rossi, J and for the Intergroupe Francais Du Myelome. (1996) A prospective, randomized trail of autologous bone marrow transplantation and chemotherapy in multiple myeloma New England Journal of Medicine, 335, pp. 91 - 97.
7. Child, J and Morgan, G and Davies, F and Owen, R and Bell, S and Hawkins, K and for the Medical Research Council Adult Leukaemia Working Party. (2003) High-dose chemotherapy and hematopoietic stem-cell rescue for multiple myeloma New England Journal of Medicine, 348, pp. 1875 - 1883.
8. Ely, S and Knowles, D. (2002) Expression of CD56/neural cell adhesion molecule correlates with the presence of lytic bone lesions in multiple myeloma and distinguishes myeloma cells from monoclonal gammopathy of undetermined significance and lymphoma with plasmacytoid differentiation American Journal of Pathology, 160, pp. 1293 - 1299.
9. Chang, H and Li, D and Zhuang, L and Nie, E and Bouman, D and Stewart, A and Chun, K. (2004) Detection of chromosome 13q deletions and IgH translocations in patients with multiple myeloma by FISH: Comparison with karyotype analysis Leukemia & Lymphoma, 45, pp. 965 - 969.
10. Pellat-Deceunynck, C and Barillle, S and Jego, G and Puthier, D and Robillard, N and Pineau, D and (1998) The absence of CD56 (NCAM) on malignant plasma cells is a hallmark of plasma cell leukemia and a special subset of multiple myeloma Leukemia, 12, pp. 1977 - 1982.
11. Raswstron, A and Barrans, S and Blythe, D and Davies, F and English, A and Pratt, G and (1999) Distribution of myeloma plasma cells in peripheral blood and bone marrow correlates with CD56 expression British Journal of Haematology, 104, pp. 138 - 143.
12. Bergsagel, P and Kuehl, W. (2001) Chromosome translocations in multiple myeloma Oncogene, 20, pp. 5611 - 5622.
13. Moreau, P and Facon, T and Leleu, X and Morineau, N and Huyghe, P and Harousseau, J and (2002) Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy Blood, 100, pp. 1579 - 1583.
14. Fonseca, R and Blood, E and Rue, M and Harrington, D and Oken, M and Kyle, R and (2003) Clinical and biologic implications of recurrent genomic aberrations in myeloma Blood, 101, pp. 4569 - 4575.
15. Chang, H and Qi, C and Yi, Q and Reece, D and Stewart, A. (2005) P53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation Blood, 105, pp. 358 - 360.